Axon Enterprise, Inc. (NASDAQ:AXON) Director Julie A. Cullivan Sells 2,013 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) Director Julie A. Cullivan sold 2,013 shares of the company’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $197.58, for a total transaction of $397,728.54. Following the completion of the sale, the director now directly owns 7,062 shares of the company’s stock, valued at approximately $1,395,309.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Axon Enterprise Stock Performance

Shares of AXON opened at $195.80 on Wednesday. Axon Enterprise, Inc. has a 12 month low of $83.01 and a 12 month high of $229.95. The firm has a fifty day simple moving average of $215.96 and a 200 day simple moving average of $197.31. The stock has a market capitalization of $14.47 billion, a price-to-earnings ratio of 103.60 and a beta of 0.95. The company has a current ratio of 3.33, a quick ratio of 2.97 and a debt-to-equity ratio of 0.48.

Axon Enterprise (NASDAQ:AXON – Get Rating) last announced its earnings results on Tuesday, February 28th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.08 by $0.28. Axon Enterprise had a net margin of 10.76% and a return on equity of 10.65%. The business had revenue of $336.14 million during the quarter, compared to analysts’ expectations of $303.91 million. Research analysts forecast that Axon Enterprise, Inc. will post 1.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXON has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $235.00 target price on shares of Axon Enterprise in a research note on Friday, April 14th. Craig Hallum increased their price objective on shares of Axon Enterprise from $215.00 to $242.00 in a research report on Wednesday, March 1st. Barclays increased their price objective on shares of Axon Enterprise from $222.00 to $256.00 in a research report on Wednesday, May 10th. StockNews.com assumed coverage on shares of Axon Enterprise in a research report on Thursday, May 18th. They set a “hold” rating for the company. Finally, TheStreet raised shares of Axon Enterprise from a “c” rating to a “b-” rating in a research report on Tuesday, May 9th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $232.64.

Institutional Trading of Axon Enterprise

Large investors have recently added to or reduced their stakes in the company. Hollencrest Capital Management acquired a new stake in Axon Enterprise in the first quarter valued at $29,000. Spire Wealth Management acquired a new stake in Axon Enterprise in the first quarter valued at $31,000. ICA Group Wealth Management LLC acquired a new stake in Axon Enterprise in the fourth quarter valued at $25,000. WealthPLAN Partners LLC acquired a new stake in Axon Enterprise in the first quarter valued at $35,000. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in Axon Enterprise in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 75.62% of the company’s stock.

Axon Enterprise Company Profile

(Get Rating)

Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.